Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study to Evaluate the Safety and Pharmacokinetics of Livmoniplimab in Combination With Budigalimab in Chinese Subjects With Locally Advanced or Metastatic Child-Pugh A Hepatocellular Carcinoma Who Have Progressed After a First-Line Regimen That Includes an Immune Checkpoint Inhibitor

NCT06487559 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT06487559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06487559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study to Evaluate the Safety and Pharmacokinetics of Livmoniplimab in Combination With Budigalimab in Chinese Subjects With Locally Advanced or Metastatic Child-Pugh A Hepatocellular Carcinoma Who Have Progressed After a First-Line Regimen That Includes an Immune Checkpoint Inhibitor
Lead sponsor
AbbVie
Phase
Phase 1
Overall status
Active, not recruiting
Start date
September 11, 2024
Completion date
February 28, 2027
Enrollment
3 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)